{
  "title": "Get medRxiv Preprint by DOI",
  "description": "Retrieve all versions of a specific preprint using its DOI. Returns metadata for each version that has been posted.",
  "request": {
    "method": "GET",
    "url": "https://api.medrxiv.org/details/medrxiv/10.1101/2021.04.29.21256344/na/json",
    "parameters": {
      "server": "medrxiv",
      "doi": "10.1101/2021.04.29.21256344",
      "format": "json"
    }
  },
  "response": {
    "status": 200,
    "body": {
      "messages": [
        {
          "status": "ok",
          "interval": "10.1101/2021.04.29.21256344",
          "cursor": "0",
          "count": 2,
          "count_new_papers": 1,
          "total": 2
        }
      ],
      "collection": [
        {
          "doi": "10.1101/2021.04.29.21256344",
          "title": "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months",
          "authors": "Thomas, SJ; Moreira, ED; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Perez, JL; Pérez Marc, G; Polack, FP; Zerbini, C; Bailey, R; Swanson, KA; Xu, X; Roychoudhury, S; Koury, K; Chakraborty, S; Seamons, OP; Xie, P; Shi, M; Yang, X; Absalon, J",
          "author_corresponding": "Thomas, SJ",
          "author_corresponding_institution": "Pfizer Inc",
          "date": "2021-04-30",
          "version": "1",
          "type": "new result",
          "license": "cc_by_nc_nd",
          "category": "infectious diseases",
          "jatsxml": "https://www.medrxiv.org/content/early/2021/04/30/2021.04.29.21256344.source.xml",
          "abstract": "Background: The BNT162b2 mRNA Covid-19 vaccine was found to be safe and 95% effective against Covid-19 through up to 2 months after the second dose.",
          "published": "10.1056/NEJMoa2110345",
          "server": "medrxiv"
        },
        {
          "doi": "10.1101/2021.04.29.21256344",
          "title": "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months",
          "authors": "Thomas, SJ; Moreira, ED; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Perez, JL; Pérez Marc, G; Polack, FP; Zerbini, C; Bailey, R; Swanson, KA; Xu, X; Roychoudhury, S; Koury, K; Chakraborty, S; Seamons, OP; Xie, P; Shi, M; Yang, X",
          "author_corresponding": "Thomas, SJ",
          "author_corresponding_institution": "Pfizer Inc",
          "date": "2021-09-08",
          "version": "2",
          "type": "confirmatory result",
          "license": "cc_by_nc_nd",
          "category": "infectious diseases",
          "jatsxml": "https://www.medrxiv.org/content/early/2021/09/08/2021.04.29.21256344.source.xml",
          "abstract": "Background: Randomized controlled trials have demonstrated vaccine safety and high efficacy against Covid-19. We report safety and efficacy of BNT162b2 through up to 6 months of follow-up.",
          "published": "10.1056/NEJMoa2110345",
          "server": "medrxiv"
        }
      ]
    }
  }
}